“Once-weekly IcoSema achieved noninferior A1c reduction and superiority in change in bodyweight, weekly total insulin dose, and hypoglycemia rates vs daily BBT [basal-bolus therapy], suggesting that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results